The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
Abstract
Purpose: Gemcitabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel. Patients and Methods: In this open-label phase II clinical trial, the primary end point was tumor response, defined as complete or partial response or stable disease lasting at least 24 weeks. A Bayesian adaptive randomization procedure was used to produce an imbalance in the randomization in favor of the superior treatment, accounting for treatment-subgroup interactions. Results: One hundred nineteen of 122 randomly assigned patients had assessable outcomes. The adaptive randomization assigned 73 patients (60%) to gemcitabine-docetaxel and 49 patients (40%) to gemcitabine alone, indicating gemcitabine-docetaxel was superior. The objective Response Evaluation Criteria in Solid Tumors response rates were 16% (gemcitabine-docetaxel) and 8% (gemcitabine). Given the data, the posterior probabilities that gemcitabine-docetaxel was superior for progression-free and overall survival were 0.98 and 0.97, respectively. Median progression-free survival was 6.2 months for gemcitabine-docetaxel and 3.0 months for gemcitabine alone; median overall survival was 17.9 months for gemcitabine-docetaxel and 11.5 months for gemcitabine. The posterior probability that patients receiving gemcitabine-docetaxel had a shorter time to discontinuation for toxicity compared with gemcitabine alone was .999. Conclusion: Gemcitabine-docetaxel yielded superior progression-free and overall survival to gemcitabine alone, but with increased toxicity. Adaptive randomization is an effective method to reduce the number of patients receiving inferior therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelman, A., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2003) · doi:10.1201/9780429258480 · Cited by 27,276
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
THOMPSON, W. R. (1933) · Biometrika · doi:10.1093/biomet/25.3-4.285 · Cited by 2,712
Modern Applied Statistics with S-PLUS
Venables, W. N., & Ripley, B. D. (1999) · Statistics and Computing · doi:10.1007/978-1-4757-3121-7 · Cited by 978
Cormier, J. N., & Pollock, R. E. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 835
Extracorporeal Circulation in Neonatal Respiratory Failure: A Prospective Randomized Study
Bartlett, R. H., Roloff, D. W., Cornell, R. G., Andrews, A. F., Dillon, P. W., & Zwischenberger, J. B. (1985) · Pediatrics · doi:10.1542/peds.76.4.479 · Cited by 768
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Self-citationApproximate Bayes factors and accounting for model uncertainty in generalised linear models
Raftery, A. (1996) · Biometrika · doi:10.1093/biomet/83.2.251 · Cited by 633
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Thall, P. F., & Cook, J. D. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00218.x · Cited by 522
Self-citationTempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., & Abbruzzese, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.140 · Cited by 519
Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1269 · Cited by 516
[Hypercoagulability and exanthematous Mediterranean fever].
Vicente, V., Moraleda, J. M., Herrero, I., & Ruiz, R. (1991) · PubMed · Cited by 493
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J.-M., & Ford, G. A. (2003) · Stroke · doi:10.1161/01.str.0000092527.33910.89 · Cited by 430
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Fletcher, C. D. M., Gustafson, P., Rydholm, A., Willén, H., & Åkerman, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3045 · Cited by 355
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Borden, E. C., Amato, D. A., Rosenbaum, C., Enterline, H. T., Shiraki, M. J., Creech, R. H., Lerner, H. J., & Carbone, P. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.840 · Cited by 299
Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes
Thall, P. F., Simon, R. M., & Estey, E. H. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140404 · Cited by 299
Self-citationPatel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M. A., Plager, C., Plunkett, W., & Benjamin, R. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3483 · Cited by 247
Self-citationLeu, K. M., Ostruszka, L. J., Shewach, D., Zalupski, M., Sondak, V., Biermann, J. S., Lee, J. S.-J., Couwlier, C., Palazzolo, K., & Baker, L. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.043 · Cited by 241
Self-citationEvidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis
Brophy, J. M., Belisle, P., & Joseph, L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00005 · Cited by 207
Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis
Bay, J., Ray‐Coquard, I., Fayette, J., Leyvraz, S., Cherix, S., Piperno‐Neumann, S., Chevreau, C., Isambert, N., Brain, E., Emile, G., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21867 · Cited by 189
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study
Merimsky, O., Meller, I., Flusser, G., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050027 · Cited by 109
Muler, J. H., McGinn, C. J., Normolle, D. P., Lawrence, T. S., Brown, D., Hejna, G., & Zalupski, M. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.129 · Cited by 104
Giles, F. J., Kantarjian, H. M., Cortes, J. E., Garcia‐Manero, G., Verstovšek, S., Faderl, S. H., Thomas, D. A., Ferrajoli, A., O'Brien, S. M., Wathen, J. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.016 · Cited by 99
Self-citationTreating COPD — The TORCH Trial, P Values, and the Dodo
Rabe, K. F. (2007) · New England Journal of Medicine · doi:10.1056/nejme068307 · Cited by 88
ASTIN: a Bayesian adaptive dose–response trial in acute stroke
Grieve, A. P., & Krams, M. (2005) · Clinical Trials · doi:10.1191/1740774505cn094oa · Cited by 81
Okuno, S. H., RYAN, L. M., Edmonson, J. H., Priebat, D. A., & Blum, R. H. (2003) · Cancer · doi:10.1002/cncr.11290 · Cited by 76
Self-citationCovariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments
Thall, P. F., & Wathen, J. K. (2005) · Statistics in Medicine · doi:10.1002/sim.2077 · Cited by 74
Self-citation
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Self-citationJudson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Metadata
- Authors
- Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., Thall, P. F., Benjamin, R. S., Baker, L. H., & Hensley, M. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-07-01
- Volume
- 25
- Issue
- 19
- Pages
- 2755-2763
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116025938
- Cited by
- 742
- References
- 35
- FWCI
- 24.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.